Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737436 | 0.87 | RIPK1 (0.51) | RIPK1MMP8CA12CA1CA7 | |
| SCHEMBL27865064 | 0.76 | ATM (0.47) | RIPK1MMP8CA12CA1CA7 | |
| SCHEMBL27785465 | 0.76 | CCKBR (0.52) | SMN1; SMN2LMNACTSKALDH1A1MAPT | |
| SCHEMBL8609659 | 0.75 | SMN1; SMN2 (0.53) | MMP8CA12CA1CA7CA14 | |
| SCHEMBL8609662 | 0.75 | SMN1; SMN2 (0.53) | MMP8CA12CA1CA7CA14 | |
| SCHEMBL5353582 | 0.74 | ALDH1A1 (0.47) | SMN1; SMN2LMNARAB9AALDH1A1GLA | |
| SCHEMBL2746269 | 0.74 | RIPK1 (0.67) | RIPK1MMP8CA1CA7CA14 | |
| SCHEMBL5249106 | 0.74 | KDM4E (0.47) | CA12CA1CA7CA14RAB9A | |
| SCHEMBL5249109 | 0.74 | KDM4E (0.47) | CA12CA1CA7CA14RAB9A | |
| SCHEMBL2239196 | 0.74 | RIPK1 (0.51) | RIPK1MMP8CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319649-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | EUTICALS GMBH (DE) | 2011-12-29 | — | — | US | claimed |
| EP-2399901-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | Archimica GmbH (DE) | 2011-12-28 | — | — | EP | claimed |
| EP-2627639-B1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10265411-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180140712-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS | 2018-05-24 | — | — | US | disclosed |
| US-9907855-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170165372-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS | 2017-06-15 | — | — | US | disclosed |
| US-9616136-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160144047-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-9226971-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140296334-A1 | N-Optionally Substituted Aryl-2-Oligomer-3-Alkoxypropionamides | NEKTAR THERAPEUTICS | 2014-10-02 | — | — | US | disclosed |
| EP-2627639-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | Nektar Therapeutics (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051551-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319649-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | NAAA, MEP1B, BCHE | RIPK1 3192/4885MMP8 1953/4885CA12 138/4885 |
| US-10265411-B2 | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | UGT1A3, AADAC, ATXN2 | RIPK1 4778/4885MMP8 2709/4885CA12 2052/4885 |
| US-20160144047-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | UGT1A3, AADAC, ATXN2 | RIPK1 4778/4885MMP8 2709/4885CA12 2052/4885 |
| US-20180140712-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | UGT1A3, AADAC, ATXN2 | RIPK1 4778/4885MMP8 2709/4885CA12 2052/4885 |
| US-20170165372-A1 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES | UGT1A3, AADAC, ATXN2 | RIPK1 4778/4885MMP8 2709/4885CA12 2052/4885 |
| US-20140296334-A1 | N-Optionally Substituted Aryl-2-Oligomer-3-Alkoxypropionamides | UGT1A3, AADAC, ATXN2 | RIPK1 4778/4885MMP8 2709/4885CA12 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.